

DAFTAR ISI

| | |
|--|------|
| HALAMAN JUDUL..... | i |
| LEMBAR PENGESAHAN | ii |
| PERNYATAAN BEBAS PLAGIASI..... | iii |
| KATA PENGANTAR | iii |
| DAFTAR ISI..... | v |
| DAFTAR GAMBAR | vii |
| DAFTAR TABEL..... | viii |
| DAFTAR LAMPIRAN | ix |
| DAFTAR SINGKATAN | x |
| INTISARI..... | xii |
| ABSTRACT..... | xiii |
| | |
| BAB I. PENDAHULUAN | 1 |
| A. Latar Belakang Penelitian | 1 |
| B. Pertanyaan Penelitian | 4 |
| C. Tujuan Penelitian | 4 |
| D. Manfaat Penelitian | 4 |
| E. Keaslian Penelitian..... | 4 |
| BAB II. TINJAUAN PUSTAKA..... | 8 |
| A. Penyakit Paru Obstruktif Kronik..... | 8 |
| A.1. Patofisiologi PPOK | 9 |
| A.2. Patogenesis PPOK..... | 10 |
| A.3. Diagnosis PPOK..... | 13 |
| A.4. Penatalaksanaan PPOK | 14 |
| B. Gangguan Kesehatan pada PPOK..... | 19 |
| C. Kualitas Hidup | 24 |
| C.1. Definisi Kualitas Hidup..... | 24 |
| C.2. Aspek Kualitas Hidup..... | 24 |
| C.3. Kualitas Hidup Penderita PPOK | 28 |

| | |
|---|-----------|
| C.4. Cara Mengukur Kualitas Hidup Penderita PPOK | 29 |
| D. Spiritualitas | 30 |
| D.1. Definisi Spiritualitas..... | 30 |
| D.2. Arti Penting Spiritualitas..... | 32 |
| D.3. Hubungan Spiritualitas dengan Kualitas Hidup..... | 35 |
| D.4. Cara Pengukuran Spiritualitas | 36 |
| E. Kerangka Teori..... | 38 |
| F. Kerangka Konsep Penelitian | 39 |
| G. Hipotesis..... | 39 |
| BAB III. METODE PENELITIAN..... | 40 |
| A. Rancangan Penelitian | 40 |
| B. Tempat dan Waktu Penelitian | 40 |
| C. Populasi Penelitian | 40 |
| D. Subjek Penelitian..... | 40 |
| E. Besar Sampel..... | 41 |
| F. Variabel Penelitian | 42 |
| G. Cara Penelitian | 42 |
| H. Analisis Statistik..... | 46 |
| I. Kelaikan Etika..... | 46 |
| J. Alur Penelitian | 47 |
| BAB IV. HASIL DAN PEMBAHASAN | 48 |
| A. Hasil | 48 |
| B. Pembahasan..... | 53 |
| BAB V. KESIMPULAN DAN SARAN..... | 59 |
| A. Kesimpulan | 59 |
| B. Saran..... | 59 |
| DAFTAR PUSTAKA | 60 |
| Lampiran 1. <i>Informed Consent</i> | 65 |
| Lampiran 2. <i>Functional Assessment on Chronic Illness Therapy – Spiritual Well-Being (FACIT-Sp)</i> | 67 |
| Lampiran 3. <i>Saint George’s Respiratory Questionnaire (SGRQ)</i> | 69 |

DAFTAR GAMBAR

| | |
|---|----|
| Gambar 1. Interaksi Komponen Seluler dan Mediator Inflamasi | 12 |
| Gambar 2. Kerangka Teori..... | 38 |
| Gambar 3. Kerangka Konsep Penelitian | 39 |
| Gambar 4. Alur Penelitian..... | 47 |

DAFTAR TABEL

| | |
|---|----|
| Tabel 1. Daftar Penelitian Spiritualitas dan Kualitas Hidup | 6 |
| Tabel 2. Indikator Variabel Diagnosa PPOK | 13 |
| Tabel 3. Klasifikasi Derajat Keparahan PPOK | 14 |
| Tabel 4. Tatalaksana Farmakologis Pasien PPOK | 17 |
| Tabel 5. Aspek-aspek Kualitas Hidup Menurut Beberapa Ahli | 26 |
| Tabel 6. Defisini Operasional Variabel Penelitian | 44 |
| Tabel 7. Karakteristik Dasar Subjek Penelitian | 49 |
| Tabel 8. Skor FACIT dan SGRQ Subjek Penelitian | 50 |
| Tabel 9. Analisis Korelasi Bivariat antar Variabel | 51 |
| Tabel 10. Analisis Korelasi Bivariat antar Domain Variabel | 52 |
| Tabel 11. Analisis Regresi Linier Variabel Independen terhadap Skor SGRQ | 53 |

DAFTAR LAMPIRAN

| | |
|--|----|
| Lampiran 1. Surat Pernyataan Persetujuan Partisipasi Penelitian..... | 64 |
| Lampiran 2. FACIT Sp-12 Questionnaire..... | 66 |
| Lampiran 3. St. George's Respiratory Questionnaire | 68 |

DAFTAR SINGKATAN

| | |
|----------|--|
| ACTH | : Adrecorticotrophine Hormone |
| ADL | : Activity daily Living |
| AP-1 | : Activator protein - 1 |
| APA | : American Psychiatric Association |
| ATP | : Adenosin trifosfat |
| COPD | : Chronic Obstructive Pulmonary Disease |
| CPBS | : Cancer Patients Behaviour Survey |
| CRP | : C-reactive protein |
| EGFR | : Endothelial growth factor receptor |
| EWB | : Existential well being |
| FACIT-Sp | : Functional Assessment on Chronic Illness Therapy – Spiritual |
| FEV | : Forced Expiration Volume |
| FVC | : Forced Vital Capacity |
| GERD | : Gastroesophageal Reflux disease |
| GOLD | : Global Initiative for Chronic Obstructive Lung Disease |
| HRQOL | : Health related Quality of Life |
| ICS | : Inhaled corticosteroid |
| IL | : Interleukin |
| IMT | : Indeks massa tubuh |
| LABA | : Long-acting β 2-adrenergic agonist |
| LAMA | : Long-acting muscarinnic antagonist |
| LFG | : Laju Filtrasi Glomerulus |
| MHREC | : Medical and Health Research Ethics committee |
| MMP | : Matrix metalloproteinase |
| NADPH | : Nicotinamide adenine dinucleotide phosphate |
| NF-kB | : Nuclear factor kappa B |
| NHLBI | : National Heart Lung and Blood institute |
| NO | : Nitrite oxide |
| PDE-4 | : Phospodiesterase-4 |

| | |
|-------|--|
| PDPI | : Perhimpunan Dokter Paru Indonesia |
| PPMPL | : Pemberantasan Penyakit Menular dan Penyehatan Lingkungan |
| PPOK | : Penyakit Paru Obstruktif Kronis |
| QOL | : Quality of Life |
| RWB | : Religious well being |
| ROS | : Reactive oxygen species |
| RSKP | : Rumah Sakit Khusus Paru |
| SABA | : Short-acting β 2-adrenergic agonist |
| SAMA | : Short-acting muscarinic antagonist |
| SBI | : Spiritual Belief Inventory |
| SGRQ | : St George's Respiratory Questionnaire |
| SKRT | : Survey Kesehatan Rumah Tangga |
| SLPI | : secretory leucocyte protease inhibitor |
| SPSS | : Statistical Package for Social science |
| SWB | : Spiritual well being |
| TBARS | : Thiobaituric acid reactive substance |
| TIMP | : Tissue inhibitors of metalloproteinase |
| TLR | : Toll-like receptor |
| TNF | : Tumor Necrosing Factor |
| WHO | : World Health Organization |